Mafodotin, referring to monomethyl auristatin F (MMAF) when employed as a cytotoxic payload in antibody–drug conjugates, is used to treat relapsed or refractory multiple myeloma. It serves as the potent toxic component in the ADC belantamab mafodotin (Blenrep), which targets B-cell maturation antigen (BCMA) on myeloma cells. Once internalized, the MMAF disrupts microtubule formation, induces cell cycle arrest, and triggers apoptotic death in malignant cells. The directory classifies it as a unknown/inactive API with a peptide source/manufacturing origin. Other names for this substance include Maleimidocaproyl monomethylauristatin F and Auristatin F derivative. Its PubChem CID is 56949327.
Mafodotin
| CAS No | 863971-19-1 |
|---|---|
| Molecular Formula | C49H76N6O11 |
| Molecular Weight | 925.20 g/mol |
| Synonyms | (2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Mafodotin, referring to monomethyl auristatin F (MMAF) when employed as a cytotoxic payload in antibody–drug conjugates, is used to treat relapsed or refractory multiple myeloma.
The listed CAS number is 863971-19-1.
The listed molecular formula is C49H76N6O11.
The listed molecular weight is 925.20 g/mol.
(2S)-2-[[(2R,3R)-3-[(2S)-1-[(3R,4S,5S)-4-[[(2S)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoyl-methylamino]-3-methylbutanoyl]amino]-3-methylbutanoyl]-methylamino]-3-methoxy-5-methylheptanoyl]pyrrolidin-2-yl]-3-methoxy-2-methylpropanoyl]amino]-3-phenylpropanoic acid.
The source lists Maleimidocaproyl monomethylauristatin F and Auristatin F derivative.